Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction (Q83111898)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

7

Robin J Shattock

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Xin Huang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Wei Jin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Kai Hu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sukun Luo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Tao Du

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

George E Griffin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Qinxue Hu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

20 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

423

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

97-106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

Gene transfer into muscle by electroporation in vivo.

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Determination of essential amino acids involved in the CD4-independent tropism of the X4 human immunodeficiency virus type 1 m7NDK isolate: role of potential N glycosylations in the C2 and V3 regions of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

A general model for the surface glycoproteins of HIV and other retroviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

7 January 2021

Candidate AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Measuring vaccine-induced HIV neutralization: report of a workshop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Measuring HIV neutralization in a luciferase reporter gene assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

GP120: target for neutralizing HIV-1 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

A role for carbohydrates in immune evasion in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Working towards an HIV/AIDS vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

The HIV vaccine pipeline, from preclinical to phase III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

7 January 2021

SnapShot: HIV-1 Proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.11.023

10.1016/J.VIROL.2011.11.023

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192629%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference